⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22970804 | 0.80 | — | — | |
| SCHEMBL17590209 | 0.78 | — | — | |
| SCHEMBL11923121 | 0.77 | — | — | |
| SCHEMBL162834 | 0.77 | — | — | |
| SCHEMBL2437225 | 0.77 | — | — | |
| SCHEMBL18504425 | 0.76 | — | — | |
| SCHEMBL8499812 | 0.76 | ALDH1A1 (0.36) | — | |
| SCHEMBL13594467 | 0.76 | — | — | |
| SCHEMBL15107342 | 0.76 | — | — | |
| SCHEMBL14141222 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170136104-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK AS (DK) | 2017-05-18 | — | — | US | disclosed |
| US-20160361427-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-12-15 | — | — | US | disclosed |
| US-20160184412-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-06-30 | — | — | US | disclosed |
| WO-2016098899-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | 日産化学工業株式会社 | 2016-06-23 | — | — | WO | disclosed |
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | NOVO NORDISK A/S (DK) | 2016-06-09 | — | — | US | disclosed |
| US-9200049-B2 | Remodeling and glycopegylation of fibroblast growth factor (FGF) | NOVO NORDISK A/S (DK) | 2015-12-01 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-9187546-B2 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-7956032-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2011-06-07 | — | — | US | disclosed |
| US-20110003744-A1 | Glycopegylated Erythropoietin Formulations | NOVO NORDISK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20100330645-A1 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20100330060-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20100113743-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100009902-A1 | Glycoconjugation Using Saccharyl Fragments | NEOSE TECHNOLOGIES, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-5214069-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-25 | — | — | US | disclosed |
| US-5132328-A | Lipoxygenase inhibitors as antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-21 | — | — | US | disclosed |
| EP-0375368-A2 | Alcohol and ether derivatives | ZENECA LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |